UK digital health platform for men's health — ED, hair loss, weight loss, and (newly) women's hormonal health.
Numan is a UK-based digital health platform that started in men's health (ED, hair loss, testosterone) and rapidly expanded into weight loss (riding the GLP-1 wave) and women's hormonal health. Revenue more than doubled to over $90M in 2024 on the back of weight-loss drug demand; the company raised $60M in 2025 to fuel the women's-health expansion.
Healthcare📍 London, United KingdomFounded 2018
Current Valuation
Private
as of 2025-Q3
PRIVATE
IPO Outlookprivate
Is Numan going public?
No. Numan is private and has not filed to go public. There is no S-1 on file.
What is Numan's valuation in 2026?
No confirmed valuation is on record for Numan. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Numan filed an S-1?
No public S-1 is on file for Numan.
Who are Numan's investors?
Numan's investors include White Star Capital, Vorwerk Ventures, Hambro Perks, Novator Ventures.
How much has Numan raised?
Numan has raised $150M in total, most recently a Series C of $60M in Jul 2025.
Is Numan publicly traded — can you buy Numan stock?
No. Numan is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Numan on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Sokratis Papafloratos
Founded
2018
HQ
London, United Kingdom
Employees
~200
Total Raised
$150M
Est. Revenue
$90M (2024-Q4)
Growth
~141% YoY
Last Round
Series C — $60M (Jul 2025) · Lead: White Star Capital
IPO Status
private
Fundraising Status
Series C · $60M · 1y 3mo ago
privateTotal raised $150M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series C
$60M
Jul 2025
White Star Capital
—
Talent Signal
Hiring trend
▶ Hiring steady
0% vs 2026-08
Open roles
8
via careers page
Product-build share
75%
engineering, research, product, design
Trajectory
steady
heavy product build — 75% of open roles are product-building functions (engineering/research/product) — 4 of 8 open roles are medical.
Counted from Numan's live job board as of 2026-09-14; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Founders & Key People
Sokratis Papafloratos
Investors
White Star Capital · Vorwerk Ventures · Hambro Perks · Novator Ventures
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q3. Refreshed quarterly.